Literature DB >> 23773151

Nociceptin / orphanin FQ (NOP) receptors as novel potential target in the treatment of gastrointestinal diseases.

Marta Sobczak1, Maciej Sałaga, Martin Storr, Jakub Fichna.   

Abstract

The nociceptin system, which consists of endogenous nociceptin/orphanin FQ and NOP receptors, is present in the central nervous system (CNS), as well as respiratory, cardiovascular, urogenital and gastrointestinal (GI) tissues. It is critically involved in nociception and pain signaling, as well as modulation of hormone and neurotransmitter release, stress responses and reversal of stress-induced analgesia. In the GI tract, the nociceptin system participates in the maintenance of homeostasis by affecting secretion and motility. Here we give an overview on the nociceptin system in the GI tract. The nociceptin system is an attractive target for novel drugs, which may be effective in the treatment of inflammatory or functional GI disorders, such as inflammatory bowel diseases (IBD) and irritable bowel syndrome (IBS).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23773151     DOI: 10.2174/13894501113149990174

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  8 in total

Review 1.  Functional plasticity of the N/OFQ-NOP receptor system determines analgesic properties of NOP receptor agonists.

Authors:  W Schröder; D G Lambert; M C Ko; T Koch
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

2.  Parsing the hedonic and motivational influences of nociceptin on feeding using licking microstructure analysis in mice.

Authors:  Ian A Mendez; Nigel T Maidment; Niall P Murphy
Journal:  Behav Pharmacol       Date:  2016-09       Impact factor: 2.293

Review 3.  Central N/OFQ-NOP Receptor System in Pain Modulation.

Authors:  Norikazu Kiguchi; Huiping Ding; Mei-Chuan Ko
Journal:  Adv Pharmacol       Date:  2015-12-17

4.  Novel mixed NOP/MOP agonist BU08070 alleviates pain and inhibits gastrointestinal motility in mouse models mimicking diarrhea-predominant irritable bowel syndrome symptoms.

Authors:  Marta Sobczak; Gerta Cami-Kobeci; Maciej Sałaga; Stephen M Husbands; Jakub Fichna
Journal:  Eur J Pharmacol       Date:  2014-05-06       Impact factor: 4.432

5.  Anti-inflammatory effect of dual nociceptin and opioid receptor agonist, BU08070, in experimental colitis in mice.

Authors:  Marta Zielińska; Tanila Ben Haddou; Gerta Cami-Kobeci; Maciej Sałaga; Agata Jarmuż; Milena Padysz; Radzisław Kordek; Mariana Spetea; Stephen M Husbands; Jakub Fichna
Journal:  Eur J Pharmacol       Date:  2015-09-25       Impact factor: 4.432

6.  Cebranopadol reduces cocaine self-administration in male rats: Dose, treatment and safety consideration.

Authors:  Huimei Wei; Ting Zhang; Chang-Guo Zhan; Fang Zheng
Journal:  Neuropharmacology       Date:  2020-05-08       Impact factor: 5.273

Review 7.  Focus on current and future management possibilities in inflammatory bowel disease-related chronic pain.

Authors:  Anna Zielińska; Maciej Sałaga; Marcin Włodarczyk; Jakub Fichna
Journal:  Int J Colorectal Dis       Date:  2018-12-19       Impact factor: 2.571

8.  Evaluation of cebranopadol, a dually acting nociceptin/orphanin FQ and opioid receptor agonist in mouse models of acute, tonic, and chemotherapy-induced neuropathic pain.

Authors:  Kinga Sałat; Anna Furgała; Robert Sałat
Journal:  Inflammopharmacology       Date:  2017-10-25       Impact factor: 4.473

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.